Difference between revisions of "Cannevert Therapeutics Ltd."
From CannaQAWiki
Jump to navigationJump to searchShawndouglas (talk | contribs) (Finished adding rest of content.) |
Shawndouglas (talk | contribs) (Made inactive.) |
||
| Line 12: | Line 12: | ||
|foundation = | |foundation = | ||
|founder = | |founder = | ||
|defunct = | |defunct = May 2019<ref name="GNWVeritas19" /> | ||
|location_city = 101-2386 East Mall, Vancouver, British Columbia | |location_city = 101-2386 East Mall, Vancouver, British Columbia | ||
|location_country = Canada | |location_country = Canada | ||
| Line 32: | Line 32: | ||
|divisions = | |divisions = | ||
|subsid = | |subsid = | ||
|homepage = [ | |homepage = [http://www.cannevert.com/home.html cannevert.com] | ||
|linkedin = | |linkedin = | ||
|footnotes = | |footnotes = | ||
|intl = No | |intl = No | ||
}} | }} | ||
'''Cannevert Therapeutics Ltd.''' | '''Cannevert Therapeutics Ltd.''' conducted ''[[Cannabis]]'' research and performed chemical ''Cannabis'' [[laboratory]] testing for the country's various cannabis programs.<ref name="GoCLab18">{{cite web |url=https://www.canada.ca/en/health-canada/services/list-licensed-dealers.html |title=Laboratories licensed to conduct activities with cannabis |work=Health Canada |publisher=Government of Canada |date=17 August 2018 |accessdate=27 June 2019}}</ref> However, the entity appears to have been a victim of downsizing by parent Veritas Pharma, Inc. in 2019 and no longer appears to operate. | ||
==History== | ==History== | ||
The company was formally founded in June 2014.<ref name="CACLACan">{{cite web |url=https://beta.canadasbusinessregistries.ca/search/results?search={Cannevert}&status=Active |title=Cannevert Therapeutics Ltd |work=Canada's Business Registries |publisher=Canadian Association of Corporate Law Administrators |accessdate=28 June 2019}}</ref> In December 2015, Veritas Pharma, Inc., "an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions," announced it would begin investing in Cannevert.<ref name="VeritasVeritas16">{{cite web |url=http://veritaspharmainc.com/2016/02/16/veritas-presents-its-key-cannevert-scientists/ |title=Veritas Presents Its Key Cannevert Scientists |publisher=Veritas Pharma, Inc |date=16 February 2016}}</ref> By May 2017, Veritas owned 80 percent of Cannevert, with an option to wholly buy the company on the table.<ref name="TNVeritas17">{{cite web |url=https://thenewswire.com/archives/BKRFNmWA-veritas-pharma-places-final-payment-in-trust-for-the-acquisition-of-cannevert-therapeutics.html |title=Veritas Pharma Places final Payment in Trust for the Acquisition of Cannevert Therapeutics |author=Veritas Pharma, Inc |work=TheNewswire |date=25 January 2017 |accessdate=28 June 2019}}</ref> In March 2018, Veritas announced the full acquisition of Cannevert, stating that the acquisition "will further enhance and extend the Company's product offering through development of the most effective cannabis strains, advancing the science behind medical cannabis, providing distribution channels for the Companies patent protected IP (cultivars & strains) products and sell or license to cancer clinics, in Canada, the US, and Europe."<ref name="GNWVeritas18">{{cite web |url=https://www.globenewswire.com/news-release/2018/03/21/1443325/0/en/Veritas-Pharma-Completes-the-100-Takeover-of-Cannevert-Therapeutics.html |title=Veritas Pharma Completes the 100% Takeover of Cannevert Therapeutics |author=Veritas Pharma, Inc |work=GlobeNewswire |date=21 March 2018 | The company was formally founded in June 2014.<ref name="CACLACan">{{cite web |url=https://beta.canadasbusinessregistries.ca/search/results?search={Cannevert}&status=Active |title=Cannevert Therapeutics Ltd |work=Canada's Business Registries |publisher=Canadian Association of Corporate Law Administrators |accessdate=28 June 2019}}</ref> In December 2015, Veritas Pharma, Inc., "an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions," announced it would begin investing in Cannevert.<ref name="VeritasVeritas16">{{cite web |url=http://veritaspharmainc.com/2016/02/16/veritas-presents-its-key-cannevert-scientists/ |title=Veritas Presents Its Key Cannevert Scientists |publisher=Veritas Pharma, Inc |date=16 February 2016}}</ref> By May 2017, Veritas owned 80 percent of Cannevert, with an option to wholly buy the company on the table.<ref name="TNVeritas17">{{cite web |url=https://thenewswire.com/archives/BKRFNmWA-veritas-pharma-places-final-payment-in-trust-for-the-acquisition-of-cannevert-therapeutics.html |title=Veritas Pharma Places final Payment in Trust for the Acquisition of Cannevert Therapeutics |author=Veritas Pharma, Inc |work=TheNewswire |date=25 January 2017 |accessdate=28 June 2019}}</ref> In March 2018, Veritas announced the full acquisition of Cannevert, stating that the acquisition "will further enhance and extend the Company's product offering through development of the most effective cannabis strains, advancing the science behind medical cannabis, providing distribution channels for the Companies patent protected IP (cultivars & strains) products and sell or license to cancer clinics, in Canada, the US, and Europe."<ref name="GNWVeritas18">{{cite web |url=https://www.globenewswire.com/news-release/2018/03/21/1443325/0/en/Veritas-Pharma-Completes-the-100-Takeover-of-Cannevert-Therapeutics.html |title=Veritas Pharma Completes the 100% Takeover of Cannevert Therapeutics |author=Veritas Pharma, Inc |work=GlobeNewswire |date=21 March 2018 |accessdate=28 June 2019}}</ref> | ||
== | In May 2019, Veritas announced a restructuring and rebuilding of Cannevert, one that would include cutting and rehiring some researchers on a contract basis. Veritas described the move as one that would "reduce costs" while scaling to better tackle analytical testing of ''Cannabis''.<ref name="GNWVeritas19">{{cite web |url=https://www.globenewswire.com/news-release/2019/05/15/1825699/0/en/Veritas-Announces-Restructuring-of-Cannevert-Therapeutics-Ltd.html |title=Veritas Announces Restructuring of Cannevert Therapeutics Ltd. |author=Veritas Pharma, Inc |work=GlobeNewswire |date=15 May 2019 |accessdate=28 June 2019}}</ref> | ||
== | |||
==Additional information== | ==Additional information== | ||
| Line 58: | Line 52: | ||
<!---Place all category tags here--> | <!---Place all category tags here--> | ||
[[Category: | [[Category:Inactive vendors]] | ||
Latest revision as of 19:00, 19 July 2022
| Former type | Incorporated (limited) |
|---|---|
| Industry | Cannabis industry |
| Genre | Cannabis testing and research |
| Defunct | May 2019[1] |
| Headquarters | 101-2386 East Mall, Vancouver, British Columbia, Canada |
| Number of locations | 1 |
| Area served | Canada |
| Key people | John Coleman |
| Services | Cannabis testing and research |
| Parent | Veritas Pharma, Inc. |
| Website | cannevert.com |
Cannevert Therapeutics Ltd. conducted Cannabis research and performed chemical Cannabis laboratory testing for the country's various cannabis programs.[2] However, the entity appears to have been a victim of downsizing by parent Veritas Pharma, Inc. in 2019 and no longer appears to operate.
History
The company was formally founded in June 2014.[3] In December 2015, Veritas Pharma, Inc., "an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions," announced it would begin investing in Cannevert.[4] By May 2017, Veritas owned 80 percent of Cannevert, with an option to wholly buy the company on the table.[5] In March 2018, Veritas announced the full acquisition of Cannevert, stating that the acquisition "will further enhance and extend the Company's product offering through development of the most effective cannabis strains, advancing the science behind medical cannabis, providing distribution channels for the Companies patent protected IP (cultivars & strains) products and sell or license to cancer clinics, in Canada, the US, and Europe."[6]
In May 2019, Veritas announced a restructuring and rebuilding of Cannevert, one that would include cutting and rehiring some researchers on a contract basis. Veritas described the move as one that would "reduce costs" while scaling to better tackle analytical testing of Cannabis.[1]
Additional information
References
- ↑ 1.0 1.1 Veritas Pharma, Inc (15 May 2019). "Veritas Announces Restructuring of Cannevert Therapeutics Ltd.". GlobeNewswire. https://www.globenewswire.com/news-release/2019/05/15/1825699/0/en/Veritas-Announces-Restructuring-of-Cannevert-Therapeutics-Ltd.html. Retrieved 28 June 2019.
- ↑ "Laboratories licensed to conduct activities with cannabis". Health Canada. Government of Canada. 17 August 2018. https://www.canada.ca/en/health-canada/services/list-licensed-dealers.html. Retrieved 27 June 2019.
- ↑ "Cannevert Therapeutics Ltd". Canada's Business Registries. Canadian Association of Corporate Law Administrators. https://beta.canadasbusinessregistries.ca/search/results?search={Cannevert}&status=Active. Retrieved 28 June 2019.
- ↑ "Veritas Presents Its Key Cannevert Scientists". Veritas Pharma, Inc. 16 February 2016. http://veritaspharmainc.com/2016/02/16/veritas-presents-its-key-cannevert-scientists/.
- ↑ Veritas Pharma, Inc (25 January 2017). "Veritas Pharma Places final Payment in Trust for the Acquisition of Cannevert Therapeutics". TheNewswire. https://thenewswire.com/archives/BKRFNmWA-veritas-pharma-places-final-payment-in-trust-for-the-acquisition-of-cannevert-therapeutics.html. Retrieved 28 June 2019.
- ↑ Veritas Pharma, Inc (21 March 2018). "Veritas Pharma Completes the 100% Takeover of Cannevert Therapeutics". GlobeNewswire. https://www.globenewswire.com/news-release/2018/03/21/1443325/0/en/Veritas-Pharma-Completes-the-100-Takeover-of-Cannevert-Therapeutics.html. Retrieved 28 June 2019.
